Focus: OH Pharmaceutical is a generic and specialty pharmaceutical manufacturer based in Crown Point, Indiana, with a heavily concentrated revenue model centered on azacitidine production. The company operates across oncology, hematology, metabolic diseases, cardiovascular, and nephrology therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow OH Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (100% of company revenue) but post-LOE generic with minimal Part D spending, indicating commoditized market position.
Help build intelligence for OH Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from OH Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Additional azacitidine formulation or manufacturer listing; post-LOE generic with no reported Part D spending.
Additional azacitidine formulation or manufacturer listing; post-LOE generic with no reported Part D spending.
Pre-launch SGLT2 inhibitor represents only pipeline asset and potential growth driver in high-value cardiovascular/metabolic space.
Rare disease indication (HAE) post-LOE; B2 receptor antagonist addresses niche orphan market with limited revenue potential.
Additional azacitidine formulation or manufacturer listing; post-LOE generic with no reported Part D spending.
Additional azacitidine formulation or manufacturer listing; post-LOE generic with no reported Part D spending.
Additional azacitidine formulation or manufacturer listing; post-LOE generic with no reported Part D spending.
Post-LOE atypical antipsychotic generic; dopamine and serotonin antagonist in commoditized psychiatric market with no reported revenue.
Post-LOE antifungal (echinocandin) for invasive candidiasis in hospital/acute care setting; niche indication with limited commercial scale.
3 discontinued, 6 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moAzacitidine supply chain instability (available/unavailable alternating status) poses operational risk and potential reputational damage in critical oncology/hematology market.